Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis

References

• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441–e441. [cited 2021 Mar 14]. https://www.nature.com/articles/bcj201650.
   PubMed Web of Science ®Google Scholar
• Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med. 2016;5, 33. [cited 2020 Dec 11]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810104/.
   PubMed Web of Science ®Google Scholar
• Pelcovits A, Niroula R. Acute myeloid leukemia: A review. R I Med J. 2020;103:38–40.
   Google Scholar
• Kamath GR, Tremblay D, Coltoff A, et al. Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. Carcinogenesis. 2019;40:651–660.
   PubMed Web of Science ®Google Scholar
• Acute Myeloid Leukemia. - Cancer Stat Facts [Internet]. SEER. 2021 [cited 2021 Mar 14]. https://seer.cancer.gov/statfacts/html/amyl.html.
   Google Scholar
• Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res. 2008;32:1221–1227.
   PubMed Web of Science ®Google Scholar
• Ventura GJ, Hester JP, Smith TL, et al. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988;27:34–37.
   PubMed Web of Science ®Google Scholar
• Korkmaz S. The management of hyperleukocytosis in 2017: Do we still need leukapheresis? Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2018;57:4–7.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhu Y, Jin Y, et al. Leukapheresis and hyperleukocytosis, Past and future. Int J Gen Med. 2021;14:3457–3467.
   PubMed Web of Science ®Google Scholar
• Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–3252. [cited 2021 Feb 21]. doi:10.1182/blood-2014-10-551507.
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 1987;5:1364–1372.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878–3885.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Stahl M, Wei W, et al. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020;61:1220–1225.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: Can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020;9, 2310. [cited 2021 Mar 22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603052/.
   PubMed Web of Science ®Google Scholar
• Ali AM, Mirrakhimov AE, Abboud CN, et al. Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest. Hematol Oncol. 2016;34:69–78. [cited 2021 Feb 21]. https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2292.
   PubMed Web of Science ®Google Scholar
• Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1–18.
   PubMed Web of Science ®Google Scholar
• Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26:117–122.
   PubMed Web of Science ®Google Scholar
• Stucki A, Rivier A-S, Gikic M, et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121–2129. [cited 2021 Feb 21]. https://www.sciencedirect.com/science/article/pii/S0006497120558217.
   PubMed Web of Science ®Google Scholar
• Stahl M, Pine A, Hendrickson JE, et al. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018;59:2723–2726.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Stahl M, Bewersdorf JP, et al. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020;13:489–499.
   PubMed Web of Science ®Google Scholar
• Ronald H, Benz EJ, Silberstein LE, Heslop H, Weitz JE, Anastasi J, Salama ME, Abutalib SE. Hematology Basic Principles and Practice. 7th ed. Philadelphia: Elsevier; 2017. p. 924–953.
   Google Scholar
• Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma. 2017;58:1–11.
   PubMed Web of Science ®Google Scholar
• Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion (Paris). 2007;47:1843–1850. [cited 2021 Mar 14]. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1537-2995.2007.01406.x.
   PubMed Web of Science ®Google Scholar
• Choi MH, Choe YH, Park Y, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion (Paris). 2018;58:208–216.
   PubMed Web of Science ®Google Scholar
• Kuo KHM, Callum JL, Panzarella T, et al. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. Br J Haematol. 2015;168:384–394. [cited 2021 Feb 27]. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13146.
   PubMed Web of Science ®Google Scholar
• Martínez-Cuadrón D, Montesinos P, Moscardo F, et al. Treatment With leukapheresis In patients diagnosed With hyperleukocytic acute myeloid leukemia. Blood. 2013;122:5046–5046. [cited 2021 Apr 8]. https://ashpublications.org/blood/article/122/21/5046/15346/Treatment-With-Leukapheresis-In-Patients-Diagnosed.
   Web of Science ®Google Scholar
• Pastore F, Pastore A, Wittmann G, et al. The role of therapeutic leukapheresis in hyperleukocytotic AML. PloS One. 2014;9:e95062.
   PubMed Web of Science ®Google Scholar
• Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020;34:3149–3160.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Giri S, Tallman MS, et al. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta-analysis. Transfusion (Paris). 2020;60:2360–2369. [cited 2021 Feb 21]. https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.15994.
   PubMed Web of Science ®Google Scholar
• Rinaldi I, Sari RM, Tedhy VU, et al. Leukapheresis does Not improve early survival outcome of acute myeloid leukemia with leukostasis patients - A dual-center Retrospective Cohort study. J Blood Med. 2021;12:623–633.
   PubMed Web of Science ®Google Scholar
• Kasner MT, Laury A, Kasner SE, et al. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol. 2007;82:1110–1112.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Bach KQ, Vu HQ, et al. Pre-chemotherapy white blood cell depletion by therapeutic leukocytapheresis in leukemia patients: A single-institution experience. J Clin Apheresis. 2020;35:117–124.
   PubMed Web of Science ®Google Scholar
• Van de Louw A, Schneider CW, Desai RJ, et al. Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis. Leuk Lymphoma. 2016;57:1319–1326.
   PubMed Web of Science ®Google Scholar
• Villgran V, Agha M, Raptis A, et al. Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2016;55:216–220.
   PubMed Web of Science ®Google Scholar
• Berber I, Kuku I, Erkurt MA, et al. Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2015;53:185–190.
   PubMed Web of Science ®Google Scholar
• De Santis GC, de Oliveira LCO, Romano LGM, et al. Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. J Clin Apheresis. 2011;26:181–185.
   PubMed Web of Science ®Google Scholar
• Lee H, Park S, Yoon J-H, et al. The factors influencing clinical outcomes after leukapheresis in acute leukaemia. Sci Rep. 2021;11:6426. [cited 2021 Dec 12]. https://www.nature.com/articles/s41598-021-85918-8.
   PubMed Web of Science ®Google Scholar
• Tan D, Hwang W, Goh YT. Therapeutic leukapheresis in hyperleukocytic leukaemias–the experience of a tertiary institution in Singapore. Ann Acad Med Singapore. 2005;34:229–234.
   PubMed Web of Science ®Google Scholar
• Thiébaut A, Thomas X, Belhabri A, et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000;79:501–506.
   PubMed Web of Science ®Google Scholar
• Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematol Am Soc Hematol Educ Program. 2014;2014:457–460.
   PubMedGoogle Scholar
• Hölig K, Moog R. Leukocyte depletion by therapeutic Leukocytapheresis in patients with leukemia. Transfus Med Hemotherapy. 2012;39:241–245. [cited 2021 May 23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434324.
   PubMed Web of Science ®Google Scholar
• Shaz BH, et al. Chapter 71 - therapeutic leukapheresis. In: Hillyer CD, Shaz BH, Zimring JC, editor. Transfus Med hemost. San Diego: Academic Press; 2009. p. 405–406. [cited 2021 Dec 12]. https://www.sciencedirect.com/science/article/pii/B9780123744326000713.
   Google Scholar
• Malkan UY, Ozcebe OI. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2017;56:880–882.
   PubMed Web of Science ®Google Scholar
• Wong GC. Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis. Ann Hematol. 2015;94:2067–2068.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. [cited 2021 Mar 28]. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21208.
   PubMed Web of Science ®Google Scholar
• Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120:1993–2002. [cited 2021 Mar 28]. doi:10.1182/blood-2012-04-424440.
   PubMed Web of Science ®Google Scholar
• Göçer M, Kurtoğlu E. Effect of prophylactic leukapheresis on early mortality and overall survival in acute leukemia patients with hyperleukocytosis. Ther Apher Dial. [cited 2021 May 30]. https://onlinelibrary.wiley.com/doi/abs/10.1111/1744-9987.13645.
   Web of Science ®Google Scholar